Client Story

EUSA Pharma

London-based pharmaceutical company EUSA Pharma markets new drugs to combat serious diseases.

 

We were informed by the equity firm Essex Woodlands, which had invested in EUSA Pharma, and by the latter company itself that it was on the look-out for innovative drugs as part of its growth strategy.

Strategy and Growth
Buy-Side Advisory
Healthcare and Life Sciences
Reading Time 3 minutes
Key Results
Purchase of global marketing rights to dinutuximab beta
by EUSA Pharma, quickly managed to obtain European approval.
Development of dinutuximab beta
for the treatment of neuroblastoma, the second most common solid tumor in children, by the Austrian biotech company Apeiron.
Approval of the drug
in the pipeline in the USA (as of September 2017).

The challenge

  • We were informed by the equity firm Essex Woodlands, which had invested in EUSA Pharma, and by the latter company itself that it was on the look-out for innovative drugs as part of its growth strategy.
  • EUSA Pharma was willing to acquire the rights to drugs for which approval had yet to be granted. Seizing the initiative, our pharmaceutical team went in search of a suitable drug.
Dark blue Background with multiple viruses in the front.

The solution

Thanks to its network of medics and pharmaceutical experts, the team was able to identify Apeiron´s immunotherapy for the treatment of brain tumors as a suitable target for purchase. Apeiron itself lacked the resources for marketing.

The team of consultants arranged a meeting and EUSA Pharma lost no time in taking action: European approval was applied for shortly after the completion of due diligence and conclusion of the purchase contract, and granted soon afterwards. 

The deal would not have come about without the initiative, wealth of knowledge and network of them.
Lee Morley
CEO of EUSA Pharma 

Passion for resultsWhat our 
client says

Expertise we provided

Healthcare and Life Sciences
Strategy and Growth

Ready for tomorrow?Get in touch and see how our team can help you.

Contact us
Icon: pen-white

What's new?You might also be interested in...

Insight
Article
April 2026
The Map Before the Storm
Is PE Looking at the Right AI Risk?
Insight
Article
April 2026
The strategic thesis was right. The P&L disagrees. Where to look
In private equity, value erosion rarely comes from a fundamentally flawed thesis. More often, the thesis, the priorities, and the operating model simply fail to align — quickly enough, or tightly enough — during the hold period. In tech-enabled industrials, that gap tends to be wider, more persistent, and more expensive to recover from
Insight
Brochure
April 2026
M&A Industry Snapshot: The European PropTech and ConTech M&A market
The European PropTech and ConTech M&A market is regaining momentum, but under fundamentally changed dynamics. Capital has become more selective, strategic buyers are increasingly dominating transaction processes, and single-point solutions are losing relevance despite strong growth.This snapshot highlights a clear shift toward scalable SaaS platforms with recurring revenues, deep workflow integration, and strong data foundations. Buy-and-build strategies remain the primary growth lever for investors, while AI-enabled platforms combining operational data and automation capabilities are commanding increasing strategic premiums.As recent transactions such as the Consigli deal demonstrate, valuation is no longer driven by revenue alone, but by a company’s role within future platform ecosystems. As a result, well-positioned platforms benefit from an attractive exit environment, while demand for mid-market add-on acquisitions remains strong. 
See all